AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
Executive Summary
Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.
You may also be interested in...
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.
AbbVie Hit Harder By EU Humira Biosimilars Than Projected
The Q3 earnings call was the first time AbbVie management had to face the masses since the mid-October launch of adalimumab biosimilars across Europe. CEO Gonzalez predicted ex-US Humira revenue erosion of 26%-27% this year, higher than previous estimates.
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
The latest US drug development news and highlights from our Performance Tracker.